China, already gaining speed in biotechnology, is looking to further accelerate novel drug development by reducing the time ...

Over the past five years, licensing deals in the U.S. have averaged $84.8 billion. In China? Just $31.3 billion. Even with ...

Drug developer NextCure said on Monday it had signed a deal worth up to $745 million with China-based drugmaker Simcere Zaiming to develop a cancer therapy for solid tumors.

In May, Pfizer spent $1.25 billion upfront for the right to license an experimental cancer drug from China's 3SBio. That is ...